Observation of Anti-vascular Endothelial Growth Factor Therapy in Exudative Age-related Macular Degeneration, Proliferative Diabetic Retinopathy, Macular Edema, and Choroidal Neovascularization.
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Visual acuity
研究概览
简要总结
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-vascular endothelial growth factor therapy drugs. In the current study, the primary aim is to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.
详细描述
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases, including neovascular age-related macular edema, diabetic macula edema/non-proliferative diabetic retinopathy / proliferative diabetic retinopathy, retinal vein occlusions related macular edema, and choroidal neovascularization secondary to multiple retinal diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-VEGF drugs. In the current study, the primary aim is to aim to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 35 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients with neovascular age-related macular edema (nAMD), diabetic macula edema (DME)/non-proliferative diabetic retinopathy (NPDR)/ proliferative diabetic retinopathy (PDR), retinal vein occlusions related macular edema, and choroidal neovascular (CNV) secondary to multiple retinal diseases.
- •Undergo intravitreal anti-VEGF therapy
排除标准
- •unable to receive OCT examination
- •Severe corneal opacity, cataract that affect OCT examination
研究组 & 干预措施
Diabetic macula edema
Patients with new-onset and recurrent diabetic macula edema
干预措施: Ranibizumab (Drug)
Neovascular age-related macular edema
Patients with new-onset and recurrent Neovascular age-related macular edema.
干预措施: Ranibizumab (Drug)
Neovascular age-related macular edema
Patients with new-onset and recurrent Neovascular age-related macular edema.
干预措施: Aflibercept (Drug)
Neovascular age-related macular edema
Patients with new-onset and recurrent Neovascular age-related macular edema.
干预措施: Conbercept (Drug)
Diabetic macula edema
Patients with new-onset and recurrent diabetic macula edema
干预措施: Aflibercept (Drug)
Diabetic macula edema
Patients with new-onset and recurrent diabetic macula edema
干预措施: Conbercept (Drug)
Non-proliferative diabetic retinopathy/proliferative diabetic retinopathy
Patients with new-onset and recurrent non-proliferative diabetic retinopathy/proliferative diabetic retinopathy
干预措施: Ranibizumab (Drug)
Non-proliferative diabetic retinopathy/proliferative diabetic retinopathy
Patients with new-onset and recurrent non-proliferative diabetic retinopathy/proliferative diabetic retinopathy
干预措施: Aflibercept (Drug)
Non-proliferative diabetic retinopathy/proliferative diabetic retinopathy
Patients with new-onset and recurrent non-proliferative diabetic retinopathy/proliferative diabetic retinopathy
干预措施: Conbercept (Drug)
Retinal vein occlusions
Patients with new-onset and recurrent retinal vein occlusions
干预措施: Ranibizumab (Drug)
Choroidal neovascularization
Patients with new-onset and recurrent choroidal neovascularization
干预措施: Ranibizumab (Drug)
Choroidal neovascularization
Patients with new-onset and recurrent choroidal neovascularization
干预措施: Aflibercept (Drug)
Choroidal neovascularization
Patients with new-onset and recurrent choroidal neovascularization
干预措施: Conbercept (Drug)
结局指标
主要结局
Visual acuity
时间窗: 1 year
LogMAR visual acuity
Central subfield thickness
时间窗: 1 year
he central subfield is defined as the circular area 1 mm in diameter centered around the center point of the fovea
次要结局
未报告次要终点
研究者
Wenbin Wei
Director
Beijing Tongren Hospital